Sixth Tone·3 min read·medium

Developed ALS Therapy Shows Early Trial Promise

S
Sixth Tone
Developed ALS Therapy Shows Early Trial Promise
AI Summary

Researchers in China have reported promising early results for RAG-17, an experimental siRNA-based therapy for a genetic form of ALS. The small-scale trial showed that the drug was well-tolerated and successfully reduced key disease-related biomarkers.

Chinese researchers have reported encouraging early results for a domestically developed experimental therapy targeting a genetic form of amyotrophic lateral sclerosis, or ALS. In a six-patient trial published this month in Nature Medicine, the drug was generally well tolerated and reduced key disease-related biomarkers.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthsciencetechnology

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in